Author: admin

DelveInsight’s “Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Primary Biliary Cholangitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market

Some of the key facts of the Primary Biliary Cholangitis Market Report:

• The Primary Biliary Cholangitis market size was approximately USD 1,150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In September 2025, Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral treatment for certain adults with primary biliary cholangitis (PBC), from the U.S. market following a request from the U.S. Food and Drug Administration (FDA). The FDA has also placed a clinical hold on all Intercept-sponsored Ocaliva trials currently underway in the U.S., the company reported. These actions follow emerging safety concerns, as the FDA noted late last year that Ocaliva posed a risk of serious liver injury in PBC patients, including those without pre-existing cirrhosis at the start of therapy.

• In September 2025, Zydus Therapeutics plans to submit a regulatory application to the U.S. Food and Drug Administration (FDA) seeking approval for its late-stage primary biliary cholangitis (PBC) candidate, saroglitazar magnesium. The decision follows encouraging results from the Phase IIb/III EPICS-III trial (NCT05133336), in which the peroxisome proliferator-activated receptor (PPAR) agonist successfully achieved both its primary and secondary endpoints. The positive outcomes were observed in patients who had shown an inadequate response to the standard of care therapy, ursodeoxycholic acid (UDCA). In the study, saroglitazar demonstrated a 48.5% improvement in biochemical response compared with placebo in adult participants, marked by at least a 15% reduction in alkaline phosphatase (ALP) levels relative to the upper limit of normal (ULN) a critical indicator of disease progression in PBC.

• In May 2025, Dr. Falk Pharma’s norucholic acid (NCA) demonstrated encouraging outcomes in a Phase III trial for primary sclerosing cholangitis (PSC). In the pivotal NUC-5 study (NCT03872921), NCA achieved statistically significant improvements over placebo in meeting the combined primary endpoints of partially normalizing alkaline phosphatase levels—a key liver enzyme linked to PSC—and slowing disease progression as shown in histology. The therapy also showed meaningful benefits across multiple secondary endpoints, while maintaining a safety and tolerability profile comparable to placebo.

• In May 2025, Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company specializing in cardiometabolic and gastrointestinal oncology diseases, reported encouraging preclinical data for Aramchol in models of primary sclerosing cholangitis (PSC). Fibroinflammatory cholangiopathies such as PSC and primary biliary cholangitis (PBC) are characterized by cholestatic injury, inflammation, and fibrosis-induced bile duct obstruction, driving disease progression. Aramchol, a stearoyl-CoA desaturase 1 (SCD-1) inhibitor, showed both preventive and therapeutic activity against biliary fibrosis in mouse PSC models. The therapy dose-dependently lowered fibrotic marker expression, including plasminogen activator inhibitor-1 and critical hepatic stellate cell activation genes (VEGFA and PDGFB) in TGFβ-stimulated human cholangiocyte (H69) and mouse biliary epithelial cells (MLEs). Moreover, Aramchol significantly blocked TGFβ-induced hepatic fibrosis pathways while promoting PPAR signaling activity.

• In March 2025, Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company developing innovative therapies for fibro-inflammatory diseases with high unmet need, recently announced positive results from the Open Label Extension (OLE) of its Phase 2 SPRING trial evaluating nebokitug in patients with primary sclerosing cholangitis (PSC). More than 90% of eligible participants from the SPRING trial chose to continue into the OLE. In this extension, patients who had previously received nebokitug during the 15-week double-blind phase were given an additional 33 weeks of treatment, totaling up to 48 weeks, while participants originally on placebo transitioned to receive 33 weeks of nebokitug therapy.

• In January 2025, COUR Pharmaceuticals, a clinical-stage biotech company focused on developing disease-modifying therapies for immune-mediated diseases, has received Orphan Drug Designation (ODD) from the FDA for CNP-104, a treatment for primary biliary cholangitis (PBC).

• In December 2024, Gilead Sciences, Inc. (Nasdaq: GILD) announced that the CHMP of the EMA has issued a positive opinion recommending seladelpar for treating primary biliary cholangitis (PBC). The therapy is intended for use with ursodeoxycholic acid (UDCA) in adults who show an inadequate response to UDCA alone or as a monotherapy for those unable to tolerate UDCA. A final European Commission decision is expected in Q1 2025.

• In November 2024, Gilead Sciences, Inc. (Nasdaq: GILD) released interim data from its ongoing Phase 3 ASSURE study, revealing that 81% (30 of 37) of primary biliary cholangitis (PBC) patients treated with Livdelzi® (seladelpar) achieved a composite biochemical response (CBR), indicating notable improvements in PBC progression markers. Additionally, 41% (15 of 37) of participants achieved normalization of alkaline phosphatase (ALP) levels, a crucial liver function biomarker.

• In September 2024, Ipsen received conditional approval from the European Commission for Iqirvo® (elafibranor) 80 mg tablets, a treatment for primary biliary cholangitis (PBC) in adults who either do not respond well to ursodeoxycholic acid (UDCA) or cannot tolerate it. Iqirvo is a first-in-class oral peroxisome proliferator-activated receptor (PPAR) agonist that targets PPARα and PPARδ, which are thought to play key roles in regulating bile acid, inflammation, and fibrosis.

• In August 2024, The FDA granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC). Livdelzi can be used alongside ursodeoxycholic acid (UDCA) in adults who do not respond adequately to UDCA, or as a monotherapy for those who are intolerant to UDCA. It is not recommended for patients with decompensated cirrhosis.

• According to our analysis, the US reported the highest number of diagnosed prevalent cases of PBC in 2023, and these cases are anticipated to grow at a strong CAGR during the forecast period (2024–2034).

• In 2023, Germany had the highest number of diagnosed prevalent cases of PBC among the EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, with approximately 34 thousand cases, and this number is expected to grow by 2034.

• The incidence of PBC increases with age, peaking between 40 and 70 years. In 2023, our estimates show around 14 thousand cases in individuals under 40, with numbers rising steadily as age increases. The largest group, with 87 thousand cases, was in the 40–70 age range, while 43 thousand cases were reported in those aged 70 and above in the US.

• Our analysis shows a higher prevalence of PBC in females than in males, with distribution rates of 82% for females and 18% for males in the US in 2023.

• Key Primary Biliary Cholangitis Companies: CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical, Novartis, Merck Sharp & Dohme LLC, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., Calliditas Therapeutics, HighTide Biopharma Pty Ltd, Albireo, Curome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc., Biotie Therapies Corp., and others

• Key Primary Biliary Cholangitis Therapies: Seladelpar, Saroglitazar, ASC42, Obeticholic, Bezafibrate, EDP-305, CNP-104, LJN452, Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Volixibat, Elafibranor, MBX-8025, Setanaxib, HTD1801 (BUDCA), A3907, HK-660S, Cenicriviroc, PLN-74809, BTT1023, and others

• The Primary Biliary Cholangitis epidemiology based on gender analyzed that Primary Biliary Cholangitis (PBC) is seen more among females than in males

• The Primary Biliary Cholangitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Primary Biliary Cholangitis pipeline products will significantly revolutionize the Primary Biliary Cholangitis market dynamics.

Primary Biliary Cholangitis Overview

Primary Biliary Cholangitis (PBC), previously known as Primary Biliary Cirrhosis, is a chronic autoimmune liver disease that primarily affects the small bile ducts within the liver. Over time, these ducts become damaged and inflamed, leading to the buildup of bile (a digestive fluid) in the liver, which can subsequently cause liver damage and scarring (cirrhosis).

To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis Market Forecast

Primary Biliary Cholangitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Primary Biliary Cholangitis Epidemiology Segmentation:

The Primary Biliary Cholangitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Primary Biliary Cholangitis

• Prevalent Cases of Primary Biliary Cholangitis by severity

• Gender-specific Prevalence of Primary Biliary Cholangitis

• Diagnosed Cases of Episodic and Chronic Primary Biliary Cholangitis

Download the report to understand which factors are driving Primary Biliary Cholangitis epidemiology trends @ Primary Biliary Cholangitis Epidemiology Forecast

Primary Biliary Cholangitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Biliary Cholangitis market or expected to get launched during the study period. The analysis covers Primary Biliary Cholangitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Primary Biliary Cholangitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Primary Biliary Cholangitis Therapies and Key Companies

• Seladelpar: CymaBay Therapeutics, Inc.

• Saroglitazar: Zydus Therapeutics Inc.

• ASC42: Gannex Pharma Co., Ltd.

• Obeticholic: Nanjing Chia-tai Tianqing Pharma

• Bezafibrate: Intercept Pharmaceuticals

• EDP-305: Enanta Pharmaceuticals

• CNP-104: COUR Pharmaceutical

• LJN452: Novartis

• Emtricitabine (FTC)/Tenofovir Disoproxil (TDF): Merck Sharp & Dohme LLC

• Volixibat: Mirum Pharmaceuticals, Inc.

• Elafibranor: Genfit

• MBX-8025: CymaBay Therapeutics, Inc.

• Setanaxib: Calliditas Therapeutics

• HTD1801 (BUDCA): HighTide Biopharma Pty Ltd

• A3907: Albireo

• HK-660S: Curome Biosciences

• Cenicriviroc: Tobira Therapeutics, Inc.

• Volixibat: Mirum Pharmaceuticals

• PLN-74809: Pliant Therapeutics, Inc.

• BTT1023: Biotie Therapies Corp.

Discover more about therapies set to grab major Primary Biliary Cholangitis market share @ Primary Biliary Cholangitis Treatment Landscape

Primary Biliary Cholangitis Market Drivers

• Increasing Disease Awareness and Early Diagnosis: Improved liver function testing and awareness among hepatologists are leading to earlier identification of PBC patients.

• Rising Prevalence in Women: PBC predominantly affects middle-aged women, and growing recognition of autoimmune liver diseases is expanding the diagnosed population.

• Advancements in Second-Line Therapies: Beyond ursodeoxycholic acid (UDCA), newer agents such as obeticholic acid (OCA) and emerging PPAR agonists are driving treatment innovation.

• Robust Pipeline Development: Late-stage candidates including seladelpar (PPAR-δ agonist) and other FXR/PPAR modulators are enhancing therapeutic options.

Primary Biliary Cholangitis Market Barriers

• High Cost of Advanced Therapies: Novel second-line and pipeline drugs are expensive, limiting accessibility in price-sensitive regions.

• Limited Patient Pool: As a rare disease, the smaller target population restricts overall market expansion.

• Safety Concerns with Existing Treatments: Some therapies, including OCA, have faced safety warnings and regulatory scrutiny, impacting physician confidence.

• Delayed Diagnosis in Early Stages: Asymptomatic presentation in early disease stages often results in late detection.

• Strict Regulatory Requirements: Clinical trials in rare liver diseases face recruitment challenges and long approval timelines.

Scope of the Primary Biliary Cholangitis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Primary Biliary Cholangitis Companies: CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical, Novartis, Merck Sharp & Dohme LLC, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., Calliditas Therapeutics, HighTide Biopharma Pty Ltd, Albireo, Curome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc., Biotie Therapies Corp., and others

• Key Primary Biliary Cholangitis Therapies: Seladelpar, Saroglitazar, ASC42, Obeticholic, Bezafibrate, EDP-305, CNP-104, LJN452, Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Volixibat, Elafibranor, MBX-8025, Setanaxib, HTD1801 (BUDCA), A3907, HK-660S, Cenicriviroc, PLN-74809, BTT1023, and others

• Primary Biliary Cholangitis Therapeutic Assessment: Primary Biliary Cholangitis current marketed and Primary Biliary Cholangitis emerging therapies

• Primary Biliary Cholangitis Market Dynamics: Primary Biliary Cholangitis market drivers and Primary Biliary Cholangitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Primary Biliary Cholangitis Unmet Needs, KOL’s views, Analyst’s views, Primary Biliary Cholangitis Market Access and Reimbursement

To know more about Primary Biliary Cholangitis companies working in the treatment market, visit @ Primary Biliary Cholangitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Primary Biliary Cholangitis Market Report Introduction

2. Executive Summary for Primary Biliary Cholangitis

3. SWOT analysis of Primary Biliary Cholangitis

4. Primary Biliary Cholangitis Patient Share (%) Overview at a Glance

5. Primary Biliary Cholangitis Market Overview at a Glance

6. Primary Biliary Cholangitis Disease Background and Overview

7. Primary Biliary Cholangitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Primary Biliary Cholangitis

9. Primary Biliary Cholangitis Current Treatment and Medical Practices

10. Primary Biliary Cholangitis Unmet Needs

11. Primary Biliary Cholangitis Emerging Therapies

12. Primary Biliary Cholangitis Market Outlook

13. Country-Wise Primary Biliary Cholangitis Market Analysis (2020–2034)

14. Primary Biliary Cholangitis Market Access and Reimbursement of Therapies

15. Primary Biliary Cholangitis Market Drivers

16. Primary Biliary Cholangitis Market Barriers

17. Primary Biliary Cholangitis Appendix

18. Primary Biliary Cholangitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing Pharm

DelveInsight’s “Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Obsessive Compulsive Disorder Market Report –

https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market

Some of the key facts of the Obsessive Compulsive Disorder Market Report:

• The Obsessive Compulsive Disorder market size was valued approximately USD 1,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In August 2025, neurocare group AG has obtained FDA clearance for its Apollo TMS Therapy device for the treatment of Obsessive-Compulsive Disorder (OCD), broadening the range of non-invasive mental health treatment options available.

• In December 2024, Obsessive-compulsive disorder (OCD) can be highly resistant to standard therapies, significantly affecting patients’ quality of life. In a groundbreaking effort, researchers conducted the first-ever clinical trial using magnetic resonance-guided focused ultrasound (MRgFUS) capsulotomy for individuals with treatment-resistant OCD. A decade-long follow-up revealed lasting symptom relief, improved daily functioning, and strong patient satisfaction. These findings highlight MRgFUS capsulotomy as a promising, safe, and effective treatment option, bringing renewed hope to OCD patients globally.

• In 2023, the market size of Obsessive Compulsive Disorder in the United States was approximately USD 600 million.

• In 2023, selective serotonin reuptake inhibitors (SSRIs) generated roughly USD 290 million in revenue across the seven major markets, while antipsychotics followed, earning around USD 160 million.

• In 2023, the market size for Obsessive Compulsive Disorder in the EU4 countries and the UK was approximately USD 380 million.

• In 2023, the United States had approximately 2.1 million diagnosed prevalent cases of Obsessive Compulsive Disorder.

• In 2023, the 7MM had around 320,000 mild cases, 760,000 moderate cases, and 1,100,000 severe cases of Obsessive Compulsive Disorder.

• In 2023, approximately 22% of Obsessive Compulsive Disorder cases in the EU4 and the UK were male, while about 78% were female.

• Key Obsessive Compulsive Disorder Companies: Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others

• Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim®, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others

• The Obsessive Compulsive Disorder epidemiology based on gender analyzed that the occurrence of gender-specific cases of Obsessive Compulsive Disorder is more in females than in males

• The Obsessive Compulsive Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obsessive Compulsive Disorder pipeline products will significantly revolutionize the Obsessive Compulsive Disorder market dynamics.

Obsessive Compulsive Disorder Overview

Obsessive-Compulsive Disorder (OCD) is a mental health condition characterized by persistent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) performed to alleviate anxiety. These behaviors often interfere with daily activities and can significantly impact an individual’s quality of life. Common obsessions include fears of contamination or harm, while compulsions might involve excessive cleaning, checking, or organizing. OCD affects both adults and children and typically requires treatment through therapy, medication, or a combination of both to manage symptoms effectively.

To Know in detail about the OCD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obsessive Compulsive Disorder Market Forecast

Obsessive Compulsive Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obsessive Compulsive Disorder Epidemiology Segmentation:

The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Obsessive Compulsive Disorder

• Prevalent Cases of Obsessive Compulsive Disorder by severity

• Gender-specific Prevalence of Obsessive Compulsive Disorder

• Diagnosed Cases of Episodic and Chronic Obsessive Compulsive Disorder

Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @ Obsessive Compulsive Disorder Epidemiology Forecast

Obsessive Compulsive Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obsessive Compulsive Disorder market or expected to get launched during the study period. The analysis covers Obsessive Compulsive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obsessive Compulsive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obsessive Compulsive Disorder Therapies and Key Companies

• Troriluzole: Biohaven Pharmaceuticals, Inc.

• Fluvoxamine maleate: AbbVie

• BHV-4157: Biohaven Pharmaceuticals, Inc.

• Quetiapine: AstraZeneca

• Reclaim®: MedtronicNeuro

• Bitopertin: Hoffmann-La Roche

• topiramate: Ortho-McNeil Pharmaceutical

• Escitalopram: Forest Laboratories

• Duloxetine: Eli Lilly and Company

• Topiramate: Janssen-Ortho Inc

• Paliperidone: Ortho-McNeil Janssen Scientific

• pregabalin: Pfizer

Discover more about therapies set to grab major Obsessive Compulsive Disorder market share @ Obsessive Compulsive Disorder Treatment Market

Obsessive Compulsive Disorder Market Drivers

• Negative lifestyle practices like unhealthy eating habits,smoking, lack of abundant sleep, and sedentary routine further proliferate anxiety disorders among individuals.

• Even though the emerging pipeline for OCD is not robust, the expected approval of troriluzole, a late-stage drug candidate with novel MoA, would drive the market.

Obsessive Compulsive Disorder Market Barriers

• SRIs, antipsychotics, mood stabilizers, and CBT are the mainstay of treatment for OCD. Therapies with novel MoAs are required to exhibit better efficacy and fewer side effects.

• Although several clinical, environmental, and biological predictors of response have been reported, delivering more personalized treatments for OCD is not a reality thus far.

Scope of the Obsessive Compulsive Disorder Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Obsessive Compulsive Disorder Companies: Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others

• Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim®, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others

• Obsessive Compulsive Disorder Therapeutic Assessment: Obsessive Compulsive Disorder current marketed and Obsessive Compulsive Disorder emerging therapies

• Obsessive Compulsive Disorder Market Dynamics: Obsessive Compulsive Disorder market drivers and Obsessive Compulsive Disorder market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Obsessive Compulsive Disorder Unmet Needs, KOL’s views, Analyst’s views, Obsessive Compulsive Disorder Market Access and Reimbursement

To know more about Obsessive Compulsive Disorder companies working in the treatment market, visit @ Obsessive Compulsive Disorder Clinical Trials and Therapeutic Assessment

Table of Contents

1. Obsessive Compulsive Disorder Market Report Introduction

2. Executive Summary for Obsessive Compulsive Disorder

3. SWOT analysis of Obsessive Compulsive Disorder

4. Obsessive Compulsive Disorder Patient Share (%) Overview at a Glance

5. Obsessive Compulsive Disorder Market Overview at a Glance

6. Obsessive Compulsive Disorder Disease Background and Overview

7. Obsessive Compulsive Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Obsessive Compulsive Disorder

9. Obsessive Compulsive Disorder Current Treatment and Medical Practices

10. Obsessive Compulsive Disorder Unmet Needs

11. Obsessive Compulsive Disorder Emerging Therapies

12. Obsessive Compulsive Disorder Market Outlook

13. Country-Wise Obsessive Compulsive Disorder Market Analysis (2020–2034)

14. Obsessive Compulsive Disorder Market Access and Reimbursement of Therapies

15. Obsessive Compulsive Disorder Market Drivers

16. Obsessive Compulsive Disorder Market Barriers

17. Obsessive Compulsive Disorder Appendix

18. Obsessive Compulsive Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obsessive Compulsive Disorder Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Biohaven Pharma, AbbVie, Biohaven Pharma, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche

“Pulmonary Fibrosis Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Fibrosis Market.

The Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight

Some of the key takeaways from the Pulmonary Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

• Pulmonary Fibrosis companies working in the treatment market are Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others, are developing therapies for the Pulmonary Fibrosis treatment

• Emerging Pulmonary Fibrosis therapies in the different phases of clinical trials are- BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others are expected to have a significant impact on the Pulmonary Fibrosis market in the coming years.

• In February 2026, PureTech Health plc (Nasdaq: PRTC; LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics organization focused on translating scientific innovation into meaningful value, has announced that both the U.S. Food and Drug Administration (FDA) and the European Commission have granted Orphan Drug Designation to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and life-threatening lung disorder. Deupirfenidone is being developed by Celea Therapeutics, a Founded Entity created by PureTech to oversee the therapy’s late-stage clinical advancement and potential commercialization.

• In February 2025, Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AK3280, an innovative anti-fibrotic candidate developed for the treatment of idiopathic pulmonary fibrosis (IPF). With this regulatory clearance, ArkBio is now authorized to commence a Phase 2 proof-of-concept (PoC) clinical trial of AK3280 in the United States. The upcoming Phase 2 trial will be conducted across multiple centers and will follow a randomized, partially double-blind, placebo- and active-controlled design. The study aims to assess the efficacy, safety, and pharmacokinetic profile of orally administered AK3280 in patients diagnosed with IPF. Approval to advance into a U.S.-based Phase 2 clinical study marks a key achievement in the global clinical development program for AK3280.

• In November 2025, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage biotech company focused on developing treatments for unmet needs in CNS, inflammatory, and cardiometabolic disorders, announced that the European Patent Office (EPO) has granted European Patent 3749324. This patent covers the use of brilaroxazine for treating pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The new patent strengthens the drug’s global protection portfolio, which already includes the United States, China, and Japan. Additionally, brilaroxazine has been granted Orphan Drug Designation by the U.S. FDA for IPF treatment.

• In September 2025, PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company focused on advancing innovative science into impactful treatments, shared new data from the open-label extension (OLE) of its Phase 2b ELEVATE IPF trial evaluating deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF). Results revealed that participants who had previously received placebo or pirfenidone for 26 weeks in the randomized phase and then transitioned to deupirfenidone for another 26 weeks in the OLE showed stabilized lung function. Presented as a late-breaking oral session at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, these outcomes underscore deupirfenidone’s potential as a future standard of care in IPF treatment.

• In September 2025, United Therapeutics is seeking approval for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) following positive results from a Phase III trial. In the TETON-2 study (NCT05255991), the inhaled prostacyclin mimetic significantly improved forced vital capacity (FVC), showing a 95.6 mL increase from baseline. Since FVC is a crucial indicator of breathing restriction in IPF, this outcome is notable. Additionally, the systemic vasodilator delayed the time to the first clinical worsening event, achieving its key secondary endpoint.

• In May 2025, Endeavor BioMedicines, a clinical-stage biotech company developing treatments for serious conditions, presented a post hoc analysis from its completed Phase 2a trial of the investigational drug ENV-101 (taladegib). The findings indicated that patients with idiopathic pulmonary fibrosis (IPF) treated with ENV-101 for 12 weeks showed a marked reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend toward decreased lung fibrosis compared to placebo. This analysis, utilizing Qureight’s advanced deep learning CT technology, was highlighted in a poster presentation at the ATS 2025 International Conference.

• In February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has temporarily halted enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data review and recommendations from the independent Data Safety Monitoring Board (DSMB). However, patients already enrolled will continue participation in the trial.

• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to inhibit WISP1-driven fibrotic signaling associated with multiple severe diseases.

• In December 2024, Boston-based clinical-stage biotherapeutics company PureTech announced that its Phase IIb trial of deupirfenidone successfully met all primary and secondary endpoints, demonstrating a reduction in lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The dose-ranging study assessed deupirfenidone (LYT-100) over 26 days, revealing that the high dose effectively slowed lung degeneration. PureTech aims to position the therapy as a new standard of care (SOC) for IPF

Pulmonary Fibrosis Overview

Pulmonary fibrosis is a chronic lung disease in which the lung tissue becomes thickened, stiff, and scarred. This scarring makes it harder for the lungs to work properly, reducing their ability to deliver oxygen into the bloodstream. Over time, people with pulmonary fibrosis may experience symptoms like persistent dry cough, shortness of breath (especially during activity), fatigue, and reduced exercise tolerance. The condition can worsen progressively and may result from various causes, including environmental exposures, autoimmune diseases, infections, certain medications, or it may occur without a known cause (idiopathic pulmonary fibrosis).

Explore the latest Pulmonary Fibrosis pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Pulmonary Fibrosis Clinical Trials

Emerging Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

• BI 1015550: Boehringer Ingelheim

• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

• Pirfenidone: PureTech

• SC1011: Guangzhou JOYO Pharma

• TTI-101: Tvardi Therapeutics

• PLN-74809: Pliant Therapeutics, Inc.

• GSK3915393: GlaxoSmithKline

• HZN-825: Amgen

• BMS-986278: Bristol-Myers Squibb

• taladegib: Endeavor Biomedicines

• BI 1819479: Boehringer Ingelheim

• Axatilimab: Syndax Pharmaceuticals

• REGEND001: Regend Therapeutics

Pulmonary Fibrosis Route of Administration

Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Pulmonary Fibrosis Molecule Type Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal

• Antibody Peptides

• Polymer

• Small molecule

• Gene therapy

Pulmonary Fibrosis Pipeline Therapeutics Assessment

• Pulmonary Fibrosis Assessment by Product Type

• Pulmonary Fibrosis By Stage and Product Type

• Pulmonary Fibrosis Assessment by Route of Administration

• Pulmonary Fibrosis By Stage and Route of Administration

• Pulmonary Fibrosis Assessment by Molecule Type

• Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Pulmonary Fibrosis Report covers around 140+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Pulmonary Fibrosis product details are provided in the report. Download the Pulmonary Fibrosis pipeline report to learn more about the emerging Pulmonary Fibrosis therapies

Some of the key companies in the Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Pulmonary Fibrosis are – United Therapeutics, Bellerophon Therapeutics, and MediciNova, and others.

Pulmonary Fibrosis Pipeline Analysis:

The Pulmonary Fibrosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment.

• Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Fibrosis drugs and therapies

Pulmonary Fibrosis Pipeline Market Drivers

• Rising prevalence of IPF worldwide, particularly in aging

• populations, driving demand for new therapies.

• Advancements in diagnostics leading to earlier and more accurate disease detection.

• Strong research and development investments by pharmaceutical companies targeting novel antifibrotic and immunomodulatory mechanisms.

• Regulatory support for orphan drugs, accelerating approvals and incentivizing innovation

Pulmonary Fibrosis Pipeline Market Barriers

• Unclear disease etiology and complex pathophysiology make drug development challenging

• High failure rate in clinical trials due to limited efficacy or safety issues

• Expensive development costs for orphan disease therapies, affecting smaller biotech players

• Limited patient population makes recruitment for large-scale trials difficult

• Side effects of existing antifibrotic drugs hinder patient adherence

• Regulatory challenges in proving long-term efficacy and safety of emerging therapies

Scope of Pulmonary Fibrosis Pipeline Drug Insight

• Coverage: Global

• Key Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

• Key Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

• Pulmonary Fibrosis Therapeutic Assessment: Pulmonary Fibrosis current marketed and Pulmonary Fibrosis emerging therapies

• Pulmonary Fibrosis Market Dynamics: Pulmonary Fibrosis market drivers and Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Pulmonary Fibrosis Report Introduction

2. Pulmonary Fibrosis Executive Summary

3. Pulmonary Fibrosis Overview

4. Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Pulmonary Fibrosis Pipeline Therapeutics

6. Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Pulmonary Fibrosis Early Stage Products (Phase I)

9. Pulmonary Fibrosis Preclinical Stage Products

10. Pulmonary Fibrosis Therapeutics Assessment

11. Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pulmonary Fibrosis Key Companies

14. Pulmonary Fibrosis Key Products

15. Pulmonary Fibrosis Unmet Needs

16 . Pulmonary Fibrosis Market Drivers and Barriers

17. Pulmonary Fibrosis Future Perspectives and Conclusion

18. Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics